Daytrana

Daytrana is a brand name of methylphenidate, approved by the FDA in the following formulation(s):

DAYTRANA (methylphenidate - film, extended release; transdermal)

• 
  Manufacturer: NOVEN PHARMS INC
  
  Approval date: April 6, 2006
  
  Strength(s): 10MG/9HR (1.1MG/HR), 15MG/9HR (1.6MG/HR), 20MG/9HR (2.2MG/HR), 30MG/9HR (3.3MG/HR) ^[RLD]

Has a generic version of Daytrana been approved?

No. There is currently no therapeutically equivalent version of Daytrana available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Daytrana. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Solubility parameter based drug delivery system and method for altering drug saturation concentration
  Patent 5,958,446
  Issued: September 28, 1999
  Inventor(s): Miranda; Jesus & Sablotsky; Steven
  Assignee(s): Noven Pharmaceuticals, Inc.
  The method of adjusting the saturation concentration of a drug in a transdermal composition for application to the dermis, which comprises mixing polymers having differing solubility parameters, so as to modulate the delivery of the drug. This results in the ability to achieve a predetermined permeation rate of the drug into and through the dermis. In one embodiment, a dermal composition of the present invention comprises a drug, an acrylate polymer, and a polysiloxane. The dermal compositions can be produced by a variety of methods known in the preparation of drug-containing adhesive preparations, including the mixing of the polymers, drug, and additional ingredients in solution, followed by removal of the processing solvents. The method and composition of this invention permit selectable loading of the drug into the dermal formulation and adjustment of the delivery rate of the drug from the composition through the dermis, while maintaining acceptable shear, tack, and peel adhesive properties.
  
  Patent expiration dates:
  
  
  • December 12, 2012
    
    ✓ 
    Drug product
  
  



• 
  Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
  Patent 6,210,705
  Issued: April 3, 2001
  Inventor(s): Mantelle; Juan & Dixon; Terese A.
  Assignee(s): Noven Pharmaceuticals, NC.
  The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.
  
  Patent expiration dates:
  
  
  • September 30, 2018
    
    ✓ 
    Patent use: FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
    ✓ 
    Drug product
  
  



• 
  Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
  Patent 6,348,211
  Issued: February 19, 2002
  Inventor(s): Juan; Mantelle & Terese A.; Dixon
  Assignee(s): Noven Pharmaceuticals, Inc.
  The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.
  
  Patent expiration dates:
  
  
  • September 30, 2018
    
    ✓ 
    Patent use: FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 29, 2013 - NEW PATIENT POPULATION
  
  

See also...

• Daytrana Consumer Information (Drugs.com)
• Daytrana System Consumer Information (Wolters Kluwer)
• Daytrana transdermal Consumer Information (Cerner Multum)
• Daytrana Advanced Consumer Information (Micromedex)
• Daytrana Transdermal Advanced Consumer Information (Micromedex)
• Methylphenidate Consumer Information (Drugs.com)
• Methylphenidate Consumer Information (Wolters Kluwer)
• Methylphenidate Chewable Tablets Consumer Information (Wolters Kluwer)
• Methylphenidate Controlled-Release Capsules Consumer Information (Wolters Kluwer)
• Methylphenidate Controlled-Release Tablets Consumer Information (Wolters Kluwer)
• Methylphenidate Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Methylphenidate Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Methylphenidate Solution Consumer Information (Wolters Kluwer)
• Methylphenidate System Consumer Information (Wolters Kluwer)
• Methylphenidate Consumer Information (Cerner Multum)
• Methylphenidate transdermal Consumer Information (Cerner Multum)
• Methylphenidate Oral, Transdermal Advanced Consumer Information (Micromedex)
• Methylphenidate Transdermal Advanced Consumer Information (Micromedex)
• Methylphenidate Hydrochloride AHFS DI Monographs (ASHP)